Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease DOI Open Access
Giordano Cecchetti, Federica Agosta, Giulia Rugarli

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 20, 2024

Abstract INTRODUCTION Considerable advancements have occurred in blood-based Alzheimer’s disease (AD) biomarkers, with automated assays emerging for clinical use. Demonstrating the reliability of these systems is crucial upcoming AD therapies. METHODS This cross-sectional study a Memory Center enrolled 98 patients along continuum or affected by other neurodegenerative disorders, stratified CSF A/T status and syndrome. Plasma pTau-217, pTau-181, Aβ42/Aβ40 were measured using Lumipulse. Relationships glomerular filtration rate (GFR) explored. ROC analysis was conducted to assess diagnostic performance. RESULTS GFR effect lowered use ratios pTau-217 correlation strong. discriminated A+/T+ excellent accuracy both dementia mild cognitive impairment (AUC 0.93-0.97), outperforming pTau-181 Aβ42/Aβ40. Cutoffs displayed high DISCUSSION Lumipulse identified cutoffs exhibit group detection, facilitating future translation.

Language: Английский

Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison DOI Creative Commons
Andrea Pilotto, Virginia Quaresima,

Chiara Trasciatti

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 3, 2024

ABSTRACT Background Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer’s disease (AD). No studies have compared clinical performance p-tau217 as assessed by fully automated Lumipulse and SIMOA ALZpath p-tau217. Aim To evaluate accuracy plasma assays AD. Methods The study included 392 participants, 162 with AD, 70 other neurodegenerative diseases (NDD) CSF biomarkers 160 healthy controls. levels were measured using assays. ability both techniques discriminate AD from NDD controls was investigated ROC analyses. Results Both showed high internal consistency similar correlation p-tau181 levels. In head-to-head comparison, differentiating (area under curve [AUC] 0.952, 95%CI 0.927–0.978 vs 0.955, 0.928–0.982, respectively) HC (AUC 0.938, 0.910-0.966 0.937, 95% CI0.907-0.967 assays). Conclusions This demonstrated precision diagnosis either or semi-automated techniques.

Language: Английский

Citations

7
Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease: a real-world study DOI
Giordano Cecchetti, Federica Agosta, Giulia Rugarli

et al.

Journal of Neurology, Journal Year: 2024, Volume and Issue: 271(10), P. 6739 - 6749

Published: Aug. 22, 2024

Language: Английский

Citations

3
Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease DOI Open Access
Giordano Cecchetti, Federica Agosta, Giulia Rugarli

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 20, 2024

Abstract INTRODUCTION Considerable advancements have occurred in blood-based Alzheimer’s disease (AD) biomarkers, with automated assays emerging for clinical use. Demonstrating the reliability of these systems is crucial upcoming AD therapies. METHODS This cross-sectional study a Memory Center enrolled 98 patients along continuum or affected by other neurodegenerative disorders, stratified CSF A/T status and syndrome. Plasma pTau-217, pTau-181, Aβ42/Aβ40 were measured using Lumipulse. Relationships glomerular filtration rate (GFR) explored. ROC analysis was conducted to assess diagnostic performance. RESULTS GFR effect lowered use ratios pTau-217 correlation strong. discriminated A+/T+ excellent accuracy both dementia mild cognitive impairment (AUC 0.93-0.97), outperforming pTau-181 Aβ42/Aβ40. Cutoffs displayed high DISCUSSION Lumipulse identified cutoffs exhibit group detection, facilitating future translation.

Language: Английский

Citations

2